[1] [1] ALDOSS I, GU Z, AFKHAMI M, et al. Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy[J]. Leuk Lymphoma, 2023, 64(6): 1092-1101.

[2] [2] MALARD F, MOHTY M. Acute lymphoblastic leukaemia[J]. Lancet, 2020, 395(10230): 1146-1162.

[3] [3] FATHI E, FARAHZADI R, MONTAZERSAHEB S, et al. Epigenetic modifications in acute lymphoblastic leukemia: from cellular mechanisms to therapeutics[J]. Curr Gene Ther, 2021, 21(1): 60-71.

[4] [4] POTKA A, LEWANDOWSKI K. BCR/ABL1-like acute lymphoblastic leukemia: from diagnostic approaches to molecularly targeted therapy[J]. Acta Haematol, 2022, 145(2): 122-131.

[6] [6] MOEIN S, TENEN D G, AMABILE G, et al. SALL4: an intriguing therapeutic target in cancer treatment[J]. Cells, 2022, 11(16): 2601.

[7] [7] ABOUELNAZAR F A, ZHANG X, WANG M, et al. The new advance of SALL4 in cancer: function, regulation, and implication[J]. J Clin Lab Anal, 2023, 37(9-10): e24927.

[8] [8] SWELEM R S, ELNEELY D A, SHEHATA A A R. The study of SALL4 gene and BMI-1 gene expression in acute myeloid leukemia patients[J]. Lab Med, 2020, 51(3): 265-270.

[9] [9] MOMENILANDI M, LVY R, SOBRINO S, et al. FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice[J]. Cell, 2024, 187(11): 2817-2837. e31.

[10] [10] RGNIER P, VETILLARD M, BANSARD A, et al. FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis[J]. Cell Rep Med, 2023, 4(12): 101256.

[15] [15] SUN B, XU L, BI W, et al. SALL4 oncogenic function in cancers: mechanisms and therapeutic relevance[J]. Int J Mol Sci, 2022, 23(4): 2053.

[16] [16] IBRAHEEM F M, BADAWY R, AYOUB M A, et al. SALL4 gene expression in acute myeloid leukemia[J]. Asian Pac J Cancer Prev, 2019, 20(10): 3121-3127.

[18] [18] WILSON K R, VILLADANGOS J A, MINTERN J D. Dendritic cell Flt3-regulation, roles and repercussions for immunotherapy[J]. Immunol Cell Biol, 2021, 99(9): 962-971.

[19] [19] CUETO F J, SANCHO D. The Flt3L/Flt3 axis in dendritic cell biology and cancer immunotherapy[J]. Cancers (Basel), 2021, 13(7): 1525.

[20] [20] MILNE P, WILHELM-BENARTZI C, GRUNWALD M R, et al. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia[J]. Blood Adv, 2019, 3(20): 3052-3061.